Britain and America have secured a landmark bilateral deal that will preserve zero duties on UK medicine shipments going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the NHS. This commitment secures that duties on these crucial goods will remain at zero for a duration of 36 months.
This agreement is in response to recent warnings to significantly raise duties on branded drug imports, with increases discussed as high as double the cost.
"This agreement with the UK strengthens the international landscape for cutting-edge drugs and introduces long-overdue equity to transatlantic medicine commerce," an announcement said.
Trade Importance
Pharmaceuticals represent one of the Britain's biggest exports to the United States, which is easily the biggest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to the third quarter, the UK sold drugs valued at billions to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This guarantee protects employment, boosts capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a government official remarked.
Specific UK Commitments
The pact involves several key commitments from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a aim to double total public funding on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments were more than twenty percent.
Industry Background
The pact takes place against a protracted dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were heightened by assertions that US customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar investments have been announced toward projects in the United States.
One official stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
